VYNE Therapeutics (US:VYNE) Globenewswireยท2025-03-06 13:00Core Viewpoint - VYNE Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2024, highlighting significant progress in its clinical pipeline and upcoming data readouts for its product candidates in 2025 [1][2]. Financial Results - As of December 31, 2024, VYNE had a cash position of $61.5 million, which is expected to fund operations into the second half of 2026 [8]. - Revenues for the year ended December 31, 2024, totaled $0.5 million, an increase from $0.4 million in 2023, primarily from royalty revenue [9]. - Research and development expenses rose to $30.9 million in 2024 from $16.3 million in 2023, driven by increased costs associated with clinical trials for repibresib and VYN202 [10]. - General and administrative expenses slightly decreased to approximately $13.2 million in 2024 from $13.4 million in 2023 [11]. - The net loss for the year ended December 31, 2024, was $39.8 million, or $0.93 per share, compared to a net loss of $28.5 million, or $2.78 per share, in 2023 [12]. Pipeline Updates - VYNE is advancing its clinical pipeline with two key data readouts expected in 2025: topline results from the Phase 2b trial of repibresib gel in nonsegmental vitiligo anticipated in mid-2025, and topline results from the Phase 1b trial of VYN202 in moderate-to-severe plaque psoriasis expected by the end of 2025 [2][6]. - The Phase 2b trial of repibresib gel involves a randomized, double-blind, vehicle-controlled design with three dose cohorts (1%, 2%, or 3% concentrations) and approximately 180 subjects [7]. - The Phase 1b trial of VYN202 has been initiated, evaluating three dosing cohorts (0.25 mg, 0.5 mg, 1 mg) in subjects with moderate-to-severe plaque psoriasis [7]. Upcoming Events - VYNE will participate in the Leerink Partners Global Healthcare Conference in Miami from March 10-12, 2025, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 [5].